vaccines: Latest News

All news where vaccines is mentioned

Flu and COVID-19 surveillance report published - gov.uk
gov.uk
39%
716
Flu and COVID-19 surveillance report published
.COVID-19 activity remained stable.SARS-CoV-2 positivity remained stable at 3.7% in week 11 compared to 3.7% in the previous week. This is based on a percentage of people who test positive among those with symptoms tested at sentinel “spotter” laboratories, reported through the Respiratory DataMart surveillance system.COVID-19 case rates and positivity in Pillar 1 decreased overall and within some age, ethnic groups, and regions in week 11.Through the SIREN healthcare cohort study, the SARS-CoV-2 positivity increased in week 11 compared to the previous week.COVID-19 hospitalisations increased slightly to 1.85 per 100,000 compared to 1.76 per 100,000 in the previous week.COVID-19 ICU admissions remained low and stable at 0.06 per 100,000 in week 11.The total number of confirmed COVID-19 acute respiratory incidents decreased compared to the previous week, with 5 incidents reported in England during week 11.The highest hospital admission rate is currently in the North East at 3.44 per 100,000.Those aged 85 years and over had the highest hospital admission rate, which increased to 21.45 per 100,000, with most of the remaining age groups remaining stable.Details of the Spring 2024 COVID-19 vaccination programme will be confirmed soon by NHS England, which will be offered to those who are aged 75 years and over, residents in a care home for older adults and individuals aged 6 months and over who are immunosuppressed.Influenza activity remained stable.Influenza positivity increased slightly to 5.9% in week 11 compared to 5.3% in the previous week.
Regulatory approval of Pfizer/BioNTech vaccine for COVID-19 - gov.uk
gov.uk
53%
386
Regulatory approval of Pfizer/BioNTech vaccine for COVID-19
PDF, 165 KB, 34 pagesThis file may not be suitable for users of assistive technology.PDF, 109 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 139 KB, 28 pagesThis file may not be suitable for users of assistive technology.PDF, 110 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 137 KB, 27 pagesThis file may not be suitable for users of assistive technology.PDF, 109 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 128 KB, 27 pagesThis file may not be suitable for users of assistive technology.PDF, 108 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 118 KB, 24 pagesThis file may not be suitable for users of assistive technology.PDF, 136 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 105 KB, 22 pagesPDF, 120 KB, 7 pagesHTMLPDF, 4.12 MB, 74 pagesHTMLPDF, 540 KB, 18 pagesHTMLPDF, 130 KB, 5 pagesHTMLPDF, 163 KB, 7 pagesThe 15-minute observation period following vaccination with COVID-19 Vaccine Pfizer/BioNTech or Moderna has been removed for individuals aged 12 years and over who have no history of a severe allergic reaction (as outlined in the .) This follows careful review of the safety data by the MHRA and advice from the government’s independent Commission on Human Medicines. A temporary suspension of the 15-minute observation period for children aged 5-11 years remains in place and this will be reviewed on a regular basis.
DMCA